Experimental Section
General: Optical rotations were measured at 23 °C.
1 H and 13 C NMR spectra were recorded at 600 and 150 MHz, respectively. All assignments were confirmed with the aid of twodimensional 1 H, 1 H (COSYDFTP) or 1 H, 13 C (INVBTP) experiments using standard pulse programs. Column chromatography was performed with Silica 60 (230-400 mesh). High resolution mass spectra were obtained by the electrospray ionization method, using an Agilent 6210 TOF LC/MS high resolution magnetic sector mass spectrometer.
Enzyme Inhibition Assays: Kinetic parameters were determined by measuring the amount of glucose produced upon the addition of enzyme at increasing maltose concentrations (from 0.5 to 30 mM) in the presence of increasing inhibitor concentration (0-200 nM) by a two-step glucose oxidase assay in a 96-well plate. The enzyme was allowed to act on the maltose substrate in the presence of inhibitor for 45 minutes at 37°C. The reactions were then quenched with Tris-HCl to a final concentration of 1M. Glucose oxidase reagent (Sigma-Aldrich) was then added to each well (125μl) and the reactions were allowed to develop for 30 minutes at 37°C. Reactions were performed in quadruplicate and absorbance measured at 405 nM by a SpectraMax 190 Plate Reader (Molecular Devices). Absorbance readings were averaged to give the final value, which was compared to a glucose standard curve to determine the amount of glucose released by the enzyme from the substrate. The program KaleidaGraph 4.1 was used to fit the data to the Michaelis-Menten equation and estimate K m , K m obs (K m in the presence of the inhibitor) and V max of the catalytic subunits. K i values for each inhibitor were determined using the equation
The K i values reported for each inhibitor were determined by averaging the K i values from three different inhibitor concentrations. The weight of compounds 8 was adjusted for the presence of the major isomer. The data was also plotted on Lineweaver-Burk plots to verify that the inhibitors were acting as competitive inhibitors. The methods used for kinetic assays were reported previously. 
1,4-Dideoxy-1,4-[[2S, 3S, 4R, 5S]-2,3,4,5,6-pentahydroxyhexyl]-(R/S)-epi-seleniumylidine]-D-arabinitol chloride (7).
Compound 11 (200 mg, 0.22 mmol) was dissolved in CH 2 Cl 2 (20 mL), the mixture was cooled to -78 o C, and BCl 3 (1M solution in CH 2 Cl 2 , 3.6 mmol) was added under N 2 . The reaction mixture was stirred at the same temperature for 30 min, and then allowed to warm to -5 o C for 6 h. The reaction was cooled to -78 o C and quenched by addition of MeOH (5 mL), the solvents were removed, and the residue was co-evaporated with MeOH (2 × 5 mL). The crude residue was dissolved in H 2 O (10 mL), Amberlyst A-26 resin (200 mg) was added, and the reaction mixture was stirred at room temperature for 3 h. Filtration through cotton, followed by solvent removal gave the crude hemiacetal. The crude product was dissolved in water (8 mL), and the solution was stirred at room temperature while NaBH 4 (34 mg, 0.9 mmol) was added in small portions over 30 min. Stirring was continued for another 3 h and the mixture was acidified to pH < 4 by dropwise addition of 2M HCl. The mixture was evaporated to dryness and the residue was co-evaporated with anhydrous MeOH (3 × 30 mL). Treatment of the solid residue with 50% EtOAc:MeOH (5-10 mL) resulted in precipitation of most of the borate salt. Filtration through cotton, followed by solvent removal gave the crude compound. The residue was purified by crystallization with minimum amount of MeOH to give 7 as a colorless solid (46 mg, 52%).
[] 02-3.97 (2H, m, H-1′a,H-5b), 3.94-3.82 (5H, m, H-6′a, H-3′, H-1′b, H-1a, H-1b), 3.78-3.73 (2H, m, H-4′, H-5′b) 3.68 (1H, dd, J 6′a,6,b = 11.7 , J 5′,6′b = 5.6 Hz, H-6′b). 
